Inspra (eplerenone)

DRUG2 trials

Sponsors

Bayer, Semmelweis University

Conditions

Chronic Central Serous ChorioretinopathyHeart Failure

Phase 2

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

CompletedNCT01807221

BayerHeart Failure

Start: 2013-06-17End: 2014-12-09Updated: 2021-07-06

Phase 4

Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

CompletedNCT02462499

Semmelweis UniversityChronic Central Serous Chorioretinopathy

Start: 2014-06-30End: 2016-09-30Updated: 2016-10-18

Related Papers

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Circulation2024-09-2932 citations

First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting

Journal of Nephrology2024-09-2814 citations

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.

2016-04-29288 citations

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.

2015-02-0166 citations